Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Diaceutics ( (GB:DXRX) ) just unveiled an announcement.
Diaceutics PLC has announced that Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited have purchased ordinary shares on behalf of key personnel under the company’s Share Incentive Plan (SIP). The company has matched these purchases with a 1:1 share award, issuing 6,218 shares to the UK Trust. This move increases Diaceutics’ total shares in issue to 84,880,396, which may impact shareholder notifications under FCA rules.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £147.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Spark’s Take on GB:DXRX Stock
According to Spark, TipRanks’ AI Analyst, GB:DXRX is a Outperform.
Diaceutics’ strong technical momentum and positive corporate developments are offset by challenges in profitability and valuation concerns. The company’s strategic expansions and solid balance sheet provide a promising outlook, but immediate financial performance issues need addressing.
To see Spark’s full report on GB:DXRX stock, click here.
More about Diaceutics
Diaceutics PLC is a leading technology and solutions provider in the pharma and biotech industry. The company offers an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services, facilitated by their platform DXRX – The Diagnostics Network.
Average Trading Volume: 161,880
Technical Sentiment Signal: Strong Buy
Current Market Cap: £116.2M
See more data about DXRX stock on TipRanks’ Stock Analysis page.